The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis.
Private DNA synthesis firm Twist Bioscience said it has closed a $61 million Series D round of financing with a group of existing and new investors.
The latest financing round comes about six months after Twist completed a $37 million Series C round. Since its inception in 2013, the company has raised a total of $133 million.
Twist also said that it has secured a debt facility of up to $15 million with an additional $5 million revolving account receivable line of credit through Silicon Valley Bank. The company is able to draw upon an undisclosed portion of the loan immediately, with additional money available upon the completion of certain business milestones.
“To date, we have shipped 65 million base pairs of DNA to more than 100 customers through our high-fidelity, high-throughput gene fabrication,” Twist CEO Emily Leproust said in a statement. “We will continue to leverage the power of scale afforded by our proprietary silicon-based DNA synthesis platform, targeting a beta launch in early 2016.”
Read full, original post: Twist Bioscience Closes $61M Series D Round, Secures $20M Debt Facility